4D Molecular Therapeutics Future Growth
Future criteria checks 2/6
4D Molecular Therapeutics's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 53% per year. EPS is expected to grow by 4.4% per annum.
Key information
-1.9%
Earnings growth rate
4.4%
EPS growth rate
| Biotechs earnings growth | 21.2% |
| Revenue growth rate | 53.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Aug 06Newsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts
Jun 284D Molecular inks collaboration deal on machine learning technology
May 04We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
May 04Have Insiders Been Buying 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares?
Mar 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6 | -200 | -184 | N/A | 5 |
| 12/31/2025 | 7 | -164 | -170 | N/A | 6 |
| 12/31/2024 | 6 | -151 | -169 | -95 | 8 |
| 12/31/2023 | 21 | -101 | -79 | -76 | N/A |
| 9/30/2023 | 22 | -96 | -77 | -73 | N/A |
| 6/30/2023 | 2 | -111 | -98 | -93 | N/A |
| 3/31/2023 | 2 | -110 | -97 | -91 | N/A |
| 12/31/2022 | 3 | -107 | -98 | -87 | N/A |
| 9/30/2022 | 2 | -105 | -102 | -86 | N/A |
| 6/30/2022 | 3 | -102 | -97 | -81 | N/A |
| 3/31/2022 | 17 | -81 | -92 | -77 | N/A |
| 12/31/2021 | 18 | -71 | -78 | -69 | N/A |
| 9/30/2021 | 17 | -67 | -69 | -65 | N/A |
| 6/30/2021 | 23 | -52 | -64 | -62 | N/A |
| 3/31/2021 | 12 | -60 | -53 | -52 | N/A |
| 12/31/2020 | 14 | -57 | -52 | -51 | N/A |
| 9/30/2020 | 17 | -52 | -43 | -42 | N/A |
| 6/30/2020 | 10 | -61 | -42 | -40 | N/A |
| 3/31/2020 | 8 | -54 | -45 | -42 | N/A |
| 12/31/2019 | 7 | -49 | -40 | -37 | N/A |
| 9/30/2019 | 9 | -35 | -36 | -33 | N/A |
| 6/30/2019 | 13 | -21 | -29 | -27 | N/A |
| 3/31/2019 | 14 | -15 | -23 | -22 | N/A |
| 12/31/2018 | 14 | -10 | -17 | -16 | N/A |
| 12/31/2017 | 6 | -11 | 8 | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FDMT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FDMT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FDMT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FDMT's revenue (53% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: FDMT's revenue (53% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FDMT's Return on Equity is forecast to be high in 3 years time